Synlogic的封面图片
Synlogic

Synlogic

生物技术研究

Cambridge，Massachusetts 9,820 位关注者

Designed for Life

关注

关于我们

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company’s late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for PKU and HCU, both inborn errors of metabolism, as well as other disorders in which the disease–specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics. Research activities include a partnership with Roche focused on inflammatory bowel disease (IBD), and a collaboration with Ginkgo Bioworks in synthetic biology, which has contributed to two pipeline programs to date. For more information, please visit www.synlogictx.com

网站
https://synlogictx.com
所属行业
生物技术研究
规模
51-200 人
总部
Cambridge，Massachusetts
类型
上市公司
创立
2014
领域
Synthetic Biology、Rare Metabolic Diseases、Drug Development、nephrology、rare disease、clinical development、PKU、HCU、IBD、homocystinuria、phenylketonuria、synbio、gout、Synbio、Synthetic Biotics、rare disease和Phase 3

地点

  • 主要

    301 Binney St

    US，Massachusetts，Cambridge，02142

    获取路线

Synlogic员工

查看全部员工

相似主页

查看职位

融资

Synlogic 共 12 轮

上一轮

上市后股权

US$21,000,000.00

在 Crunchbase 上查看更多信息